Tag - MNOV

Markets

Maxim starts MediciNova at buy; PT $15

Maxim Group launched coverage of MediciNova (NASDAQ:MNOV) with a “buy” rating and $15 price target. The stock closed at $5.68 on March 9. MediciNova is developing MN-166 for neurodegenerative diseases, glioblastoma...

March 10, 2021

Developments

MediciNova reports positive results from Phase 2 alcohol use disorder trial

MediciNova (NASDAQ:MNOV) reported positive results from its Phase 2 trial evaluating ibudilast for the treatment of alcohol use disorder (AUD). Ibudilast has been marketed in Japan and Korea since 1989 to treat post...

August 6, 2020

Tag - MNOV

Maxim starts MediciNova at buy; PT $15

MediciNova reports positive results from Phase 2 alcohol use disorder trial

General

More